Pfizer’s Humira Biosimilar Gets Interchangeable Designation

Pfizer announced that the FDA has designated Abrilada (adalimumab-afzb) as an interchangeable biosimilar to Humira (adalimumab), giving pharmacists the ability to substitute it for Humira without intervention from the prescribing clinician.

The interchangeable designation applies to all approved indications of Abrilada, including patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa and uveitis.

Abrilada is one of only two biosimilars that are interchangeable with Humira. The other is Boehringer Ingelheim’s Cyltezo, which launched in July.

To read the whole story, click here to subscribe.

Related Topics